» Articles » PMID: 39412377

Advancements in Current One-size-fits-all Therapies Compared to Future Treatment Innovations for Better Improved Chemotherapeutic Outcomes: a Step-toward Personalized Medicine

Overview
Publisher Informa Healthcare
Date 2024 Oct 16
PMID 39412377
Authors
Affiliations
Soon will be listed here.
Abstract

The development of therapies followed a generalized approach for a long time, assuming that a single treatment could effectively address various patient populations. However, recent breakthroughs have revealed the limitations of this one-size-fits-all paradigm. More recently, the field of therapeutics has witnessed a shift toward other modules, including cell therapies, high molecular weight remedies, personalized medicines, and gene therapies. Such advancements in therapeutic modules have the potential to revolutionize healthcare and pave the way for medicines that are more efficient and with minimal side effects. Cell therapies have gained considerable attention in regenerative medicine. Stem cell-based therapies, for instance, hold promise for tissue repair and regeneration, with ongoing research focusing on enhancing their efficacy and safety. High molecular weight drugs like peptides and proteins emerged as promising therapeutics because of their high specificity and diverse biological functions. Engineered peptides and proteins are developed for targeted drug delivery, immunotherapy, and disease-modulation. In personalized medicine, tailored treatments to individuals based on specific genetic profiling, lifestyle, biomarkers, and disease characteristics are all implemented. Clinicians have tailored treatments to optimize outcomes and minimize adverse effects, using targeted therapies based on specific mutations, yielding remarkable results. Gene therapies have revolutionized the treatment of genetic disorders by directly targeting the underlying genetic abnormalities. Innovative techniques, such as CRISPR-Cas9 have allowed precise gene editing, opening up possibilities for curing previously incurable conditions. In conclusion, advancements in therapeutic modules have the potential to revolutionize healthcare and pave the way for medicines that are more efficient and with minimal side effects.

Citing Articles

Metformin modulates FJX1 via upregulation of Hsa-miR-1306-3p to suppress colon adenocarcinoma viability.

Kim J, Shin H, Kim W, Park E, Lee D, Lee Y Sci Rep. 2025; 15(1):6658.

PMID: 39994354 PMC: 11850875. DOI: 10.1038/s41598-025-91022-y.


Integrating transcriptomics and scPagwas analysis predicts naïve CD4 T cell-related gene DRAM2 as a potential biomarker and therapeutic target for colorectal cancer.

Feng R, Li X, Li B, Luan T, He J, Liu G BMC Cancer. 2025; 25(1):317.

PMID: 39984869 PMC: 11843817. DOI: 10.1186/s12885-025-13731-x.


Serum-derived exosomal miR-7977 combined with miR-451a as a potential biomarker for pancreatic ductal adenocarcinoma.

Chen J, Zhang X, Zhang G, Zhu F, Liu W BMC Cancer. 2025; 25(1):295.

PMID: 39972247 PMC: 11837301. DOI: 10.1186/s12885-025-13659-2.


Comprehensive insights and In silico analysis into the emerging role of LincRNAs in lung diseases pathogenesis; a step toward ncRNA precision.

Hamdy N, Zaki M, Abdelmaksoud N, Elshaer S, Abd-Elmawla M, Rizk N Funct Integr Genomics. 2025; 25(1):34.

PMID: 39912974 PMC: 11802690. DOI: 10.1007/s10142-025-01540-1.